Phase II Study of Bevacizumab and Vorinostat for Patients With Recurrent World Health Organization Grade 4 Malignant Glioma
Oncologist - United States
doi 10.1634/theoncologist.2017-0501
Full Text
Open PDFAbstract
Available in full text
Date
November 13, 2017
Authors
Publisher
Alphamed Press